Senseonics (SENS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
Meeting held virtually to improve access, encourage global participation, and reduce costs.
Board members, executive officers, outside auditors, and counsel were introduced.
Formal business followed the agenda set in the notice and proxy statement.
Board and executive committee updates
Three Class I directors nominated for election to serve until the 2029 annual meeting.
Shareholder proposals
Six proposals presented: election of directors, advisory vote on executive compensation, frequency of compensation votes, ratification of auditors, amendment to increase authorized shares, and approval of the 2026 Equity Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Senseonics
- Q1 2026 revenue rose 87% to $11.7M, with gross margin at 59% and net loss at $32.3M.SENS
Q1 202611 May 2026 - 2025 revenue up 60% to $35.3M, with 65–76% growth expected in 2026.SENS
Q4 202529 Apr 2026 - Shareholders will vote on director elections, compensation, share increase, and a new equity plan.SENS
Proxy filing9 Apr 2026 - Key proposals include director elections, share increase, and new equity plan, all board-backed.SENS
Proxy filing6 Apr 2026 - Six key proposals, including share increase and new equity plan, recommended for approval.SENS
Proxy filing6 Apr 2026 - Virtual meeting to vote on directors, compensation, share increase, and new equity plan.SENS
Proxy filing27 Mar 2026 - 2025 guidance projects $34–38M revenue and a doubling of the global patient base.SENS
Q4 202413 Feb 2026 - Q2 2025 revenue up 37% YoY to $6.6M, gross margin at 46.9%, net loss narrowed to $14.5M.SENS
Q2 20253 Feb 2026 - Launching a one-year CGM sensor and expanding partnerships to capture rapid diabetes market growth.SENS
Small-Cap Growth Virtual Investor Conference3 Feb 2026